Conference Proceedings
Clinical impact of tissue of origin testing and mutation profiling in the Solving Unknown Primary Cancer (SUPER) national prospective study: Experience of the first two years.
Linda R Mileshkin, Tharani Sivakumaran, Dariush Etemadmoghadam, Richard Tothill, Andrew Fellowes, Stephen B Fox, Lisa Guccione, Alison E Freimund, Anna Defazio, Nicholas Wilcken, Bo Gao, Madhu Sudan Singh, Ian M Collins, Gary Edward Richardson, Christopher B Steer, Mark Andrew Warren, Christos Stelios Karapetis, Cindy Bryant, Penelope Schofield, David Bowtell
JOURNAL OF CLINICAL ONCOLOGY | AMER SOC CLINICAL ONCOLOGY | Published : 2019
Abstract
3072 Background: Cancer of unknown primary (CUP) has a poor prognosis with a median survival of less than 12 months. SUPER is a prospective cohort study designed to create a national biobank of patients (pts) with no confirmed primary site following diagnostic work-up. Tumor and blood samples undergo mutational profiling for actionable mutations using the 386 gene PeterMac Comprehensive Cancer Panel (CCP) plus CUPGuide, a microarray gene-expression site-of-origin assay. We aimed to determine the clinical impact of CUPGuide and CCP profiling. Methods: 172 pts were enrolled between 2013-2015. Baseline demographics, treatments, investigations and clinico-pathological characteristics were colle..
View full abstract